Top 10 article countdown: Oncology Central 2024
As we approach 2025, we are taking the opportunity to reflect on the standout moments of the past year. At Oncology Central, we have collated the top 10 articles of 2024, including news pieces, conference coverage and exclusive interviews. We hope you enjoy our selection and look forward to what 2025 has in store.
ASCO 2024: HPV vaccine reduces head and neck cancer risk in men
Coming in 10th place is a news story from the ASCO Annual Meeting (May 31st – June 4th 2024 IL, USA). This study showed that the HPV vaccine is effective in preventing the development of several HPV-related cancers, including reducing the risk of head and neck cancer in men.
A journey through value-based oncology care
Taking the 9th place, Chevon Rariy (Oncology Care Partners, AZ, USA) speaks about how artificial intelligence and value-based care could influence healthcare delivery to create better care journeys for cancer patients, including improved treatment access and enhanced care coordination.
RNA-LPAs: the latest breakthrough in immuno-oncology
Our top news piece of 2024 discussed how researchers have developed a novel mRNA vaccine to overcome the limitations of current cancer vaccines. This innovative approach has shown promising results in its first-in-human trial and has the added benefit of being highly personalized to individual patients.
Tackling cancer inequalities – the SAMBAI project
At 7th place, a feature with Melissa Davis (Morehouse School of Medicine, GA, USA) delving into the SAMBAI project. This project sought to uncover societal, ancestry, molecular and biological factors that contribute to cancer inequities.
How is rapid innovation in chronic lymphocyte leukemia treatment impacting clinical practice?
An opinion piece with Stephan Stilgenbauer (Ulm University, Germany) and Mehrdad Mobasher (BeiGene, CA, USA), in which they discuss key advancements in treating chronic lymphocytic leukemia and how these have translated into the clinic, secures the 6th spot.
In 5th place is a clinical trial protocol published in Future Oncology, evaluating the safety and effectiveness of relugolix for prostate cancer patients in routine care. This study provides real-world data to help researchers and practitioners advance their understanding of relugolix.
ASCO 2024: lorlatinib yields longest ever PFS recorded for ALK + NSCLC
The standout news piece from our 2024 ASCO coverage was the CROWN study, demonstrating record breaking outcomes for advanced NSCLC patients receiving lorlatinib. Lead author Benjamin Soloman (Peter MacCallum Cancer Center, Australia) commented: “These long-term data results are off the chart and this study confirms the outstanding durable efficacy of lorlatinib as a first-line choice for patients…”
What does the US FDA approval of Anktiva® signify for bladder cancer?
In 3rd place, an interview with Karim Chamie (UCLA, CA, USA) discussing the recent approval of Anktiva® (N-803), the importance of IL-15 in non-muscle-invasive bladder cancer and how this relates to Anktiva’s mode of action. This interview also provides key information from the QUILT 3.032 study.
ESMO 2024: breaking news and abstracts
Nabbing the 2nd spot is our ESMO 2024 (13–17th September, Barcelona, Spain) conference coverage. Key stories noted in this roundup include breakthroughs in gynecological oncology practice-changing data for multiple cancers as well as the first proof that breastfeeding after breast cancer is safe.
ASCO 2024: breaking news, key talks and takeaways
Finally, taking 1st place is our collection of key talks and takeaways from ASCO 2024. Aside from the breakthrough story of lorlatinib, highlights from this collection include osimertinib improving progression-free survival for certain EGFR-NSCLC patients and impressive results for BrECADD in patients with Hodgkin lymphoma.
We hope you’ve enjoyed our round-up of the most read stories from across Oncology Central in 2024. Interested in more top content? View more in key topic areas now including immunotherapy, conference coverage, drug approval news and personalized medicine.